Search PubMed⌕ Search

Biomedical subjects

G Breithardt

Publications and source records attributed to G Breithardt.

At least 253 records · Page 14Linked to original sources

Optimizing defibrillation through improved waveforms.

Defibrillation of the heart is achieved if an electrical current depolarizes the majority of the unsynchronized fibrillating myocardial cells. The applied current or the corresponding voltage described as a function of time is called the waveform. In pacing, to stimulate myocardial cells close to the electrode, a relatively low voltage is needed for a relatively brief duration. However, in defibrillation, approximately a 100-fold higher voltage is needed and achieved by the use of capacitors. The exponential voltage decay of a capacitor during its discharge determines the basic waveform for defibrillation. In an attempt to lower the energy needed for defibrillation, the steepness of the decay (different capacitances), the duration (fixed duration waveforms) or tilt (fixed tilt waveforms), or the initial polarity can be changed. Additionally, the polarity of the electrodes can be reversed during the discharge of the capacitor once (biphasic waveform) or twice (triphasic waveform). If two capacitors and defibrillation pathways are available, bidirectional defibrillation pulses can be delivered sequentially. In humans, the original standard waveform used with endocardial leads was a single monophasic pulse delivered by a 125-microF capacitor using the endocardial right ventricular electrode as cathode. It is now known that a reversal of the initial polarity and a reversal of polarity during capacitor discharge may significantly lower the energy needed for defibrillation, thereby preventing formerly frequent failures of defibrillation with endocardial lead systems. The use of sequential pulses showed no or only slight reductions of energy requirements and was abandoned due to the additional electrode needed. The use of a smaller capacitance (60-90 microF reduced maximum energy output but generally did not reduce energy requirements for defibrillation. However, with more efficient electrodes, smaller capacitances that will help to reduce the size of the defibrillator might be used. Thus, today defibrillation is optimized with respect to energy, capacitor size, and ease of implantation if an approximately 90-microF capacitor is used to deliver a biphasic pulse via a bipolar lead system using the right ventricular electrode as anode.

Animals↗

Bipolar transvenous defibrillation: efficacy of two different positions of the anode.

For most nonthoracotomy defibrillation lead systems, the transvenous anode can positioned independently of the right ventricular (RV) cathode. Usually a vertical position in the superior vena cava (SVC) is chosen. However, it is unknown if this position yields the optimal defibrillation threshold (DFT). Therefore, in 15 patients undergoing defibrillator implantation the SVC position was compared in a crossover study design with a horizontal position in the left brachiocephalic vein (BCV). Mean DFT was not different for SVC and BCV (19.2 +/- 9.6 J vs 18.5 +/- 9.1 J) but DFT of individual patients differed by up to 12 joules. A positive correlation between impedance and DFT in the BCV position (r = 0.6; P < or = 0.05) indicated that the improved geometry of the defibrillation field with the BCV position is opposed by a higher impedance found for this position (63 +/- 15 omega vs 52 +/- 7 omega). Thus, defibrillation is not improved in general although individual patients might benefit.

Aged↗

Erroneous discharge of an implantable cardioverter defibrillator caused by an electric razor.

We report an unusual case of the erroneous discharge of a third-generation multiprogrammable implantable cardioverter defibrillator in a 64-year-old patient with a history of recurrent ventricular tachycardias caused by electromagnetic interference while shaving with an electric razor. Electromagnetic interference was related to a defect in the electrode's insulation and could not be provoked in an intact electrode.

Defibrillators, Implantable↗

Idiopathic left ventricular tachycardia: new insights into electrophysiological characteristics and radiofrequency catheter ablation.

OBJECTIVES: This study was performed to investigate the electrophysiological characteristics of idiopathic left ventricular tachycardia and to determine the feasibility of radiofrequency catheter ablation for nonpharmacological cure. BACKGROUND: The underlying electrophysiological mechanism of idiopathic left ventricular tachycardia with right bundle branch block morphology and left-axis deviation is presently not known. Additionally, only limited data describing the results of radiofrequency catheter ablation for treatment of idiopathic left ventricular tachycardia so far exist. METHODS: Electrophysiological studies and radiofrequency catheter ablation were performed in 5 patients (3 male and 2 female, mean age 31 +/- 10 years) with idiopathic left ventricular tachycardia (cycle length 376 +/- 72 msec). The patients had a history of recurrent palpitations of 4 +/- 1 years and had been treated unsuccessfully with 2 +/- 1 antiarrhythmic drugs. Sustained ventricular tachycardia with right bundle branch block morphology and left- or right-axis deviation was documented in all patients. RESULTS: Inducibility with critically timed ventricular extrastimuli, inverse relationships of the coupling interval of the initiating extrastimulus and the interval to the first beat of the tachycardia, continuous diastolic or mid-diastolic electrical activity during ventricular tachycardia, and fragmented late potentials during sinus rhythm suggested reentrant activation as the underlying mechanism in three patients. On the other hand, induction dependent on isoproterenol infusion and rapid ventricular pacing and exercise inducibility indicated different electrophysiological characteristics in the remaining two patients. During electrophysiological study, intravenous verapamil terminated ventricular tachycardia in all patients, whereas ventricular tachycardia did not respond to intravenous adenosine, autonomic maneuvers, or intravenous beta-blocking agent esmolol. Catheter mapping revealed earliest endocardial activation during ventricular tachycardia in different areas of the left ventricular septum being distributed from the base to the mid-apical portion of the septum in all patients. In 4 of 5 patients, radiofrequency catheter ablation (median number of pulses 4, range 1-9) resulted in complete abolition of idiopathic left ventricular tachycardia during a follow-up of 4-43 months (median 10) without antiarrhythmic drugs. Successful target sites for catheter ablation included continuous diastolic or mid-diastolic electrical activity during ventricular tachycardia and late potentials during sinus rhythm (2 patients), polyphasic fragmented presystolic potentials during ventricular tachycardia (1 patient), and pace mapping with identical QRS morphology compared to the ventricular tachycardia and "earliest" detectable activity during tachycardia (1 patient). No procedure related complications occurred. CONCLUSIONS: Two different patterns of electrophysiological properties of idiopathic left ventricular tachycardia were observed, indicating that this arrhythmia entity does not represent a homogeneous group. The "origin" of the tachycardias as identified by successful radiofrequency catheter ablation was located in different areas of the left ventricular septum and was distributed from the base to the mid-apical region. Radiofrequency catheter ablation was an effective and safe treatment modality in most of these patients. Distinct target site characteristics for successful catheter ablation including polyphasic diastolic activity during tachycardia and fragmented late potentials during sinus rhythm could be identified.

Adult↗

Internal defibrillation with smaller capacitors: a prospective randomized cross-over comparison of defibrillation efficacy obtained with 90-microF and 125-microF capacitors in humans.

INTRODUCTION: The size of current implantable cardioverter defibrillators (ICD) is still large in comparison to pacemakers and thus not convenient for pectoral implantation. One way to reduce ICD size is to defibrillate with smaller capacitors. A trade-off exists, however, since smaller capacitors may generate a lower maximum energy output. METHODS AND RESULTS: In a prospective randomized cross-over study, the step-down defibrillation threshold (DFT) of an experimental 90-microF biphasic waveform was compared to a standard 125-microF biphasic waveform. The 90-microF capacitor delivered the same energy faster and with a higher peak voltage but provided only a maximum energy output of 20 instead of 34 J. DFTs were determined intraoperatively in 30 patients randomized to receive either an endocardial (n = 15) or an endocardial-subcutaneous array (n = 15) defibrillation lead system. Independent of the lead system used, energy requirements did not differ at DFT for the experimental and the standard waveforms (10.3 +/- 4.1 and 9.5 +/- 4.9 J, respectively), but peak voltages were higher for the experimental waveform than for the standard waveform (411 +/- 80 and 325 +/- 81 V, respectively). For the experimental waveform the DFT w as 10 J or less using an endocardial lead-alone system in 10 (67%) of 15 patients and in 12 (80%) of 15 patients using an endocardial-subcutaneous array lead system. CONCLUSIONS: A shorter duration waveform delivered by smaller capacitors does not increase defibrillation energy requirements and might reduce device size. However, the smaller capacitance reduces the maximum energy output. If a 10-J safety margin between DFT and maximum energy output of the ICD is required, only a subgroup of patients will benefit from 90-microF ICDs with DFTs feasible using current defibrillation lead systems.

Adolescent↗

Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest.

BACKGROUND: The availability of implantable cardioverter-defibrillators (ICD) that are capable of antitachycardia pacing may lead to an increased use of ICDs in patients with haemodynamically tolerated ventricular tachycardia without a history of cardiac arrest. The frequency of potentially life-threatening fast ventricular tachycardias (cycle length < 250 ms) was investigated in patients who had a third generation ICD with endocardial leads implanted because they had haemodynamically tolerated ventricular tachycardia without a history of cardiac arrest. METHODS: Between January 1990 and October 1993, 50 patients (age (mean (SD)) 60 (11); ejection fraction 39 (16)%; 82% with coronary artery disease and 8% with dilated cardiomyopathy) with haemodynamically tolerated ventricular tachycardia (cycle length (mean (SD)) 348 (60) ms; range 250-500 ms) and without a history of cardiac arrest were treated with third generation ICDs that were capable of antitachycardia pacing. Fast ventricular tachycardia had been induced in 14 (28%) during baseline electrophysiological study. The benefit of ICD treatment was estimated as the difference between total mortality and the occurrence of fast ventricular tachycardia that would have been fatal if it had not been terminated. RESULTS: During follow up of 17 (12) months, 33 patients (66%) had a total of 3861 episodes of ventricular tachycardia. 91% of these episodes were terminated by antitachycardia pacing. 11 patients (22%) had episodes of potentially life-threatening fast ventricular tachycardia and 3 of these also had inducible fast ventricular tachycardia. One patient died suddenly 27 months after implantation. The difference between survival without fast ventricular tachycardia and total mortality was 9%, 12%, 27%, and 27% at 6, 12, 18, and 24 months, respectively. CONCLUSIONS: About a fifth of patients who had been given an ICD to treat haemodynamically tolerated ventricular tachycardia and who had no history of cardiac arrest experienced fast ventricular tachycardia during follow up requiring immediate cardioversion. Prospective studies are needed to investigate whether the prognosis of patients with a history of haemodynamically tolerated ventricular tachycardia without cardiac arrest is improved by ICD therapy.

Cardiomyopathy, Dilated↗

[Single left coronary artery after orthotopic heart transplantation: angiography and intravascular ultrasound findings].

A 23-year-old man underwent orthotopic heart transplantation due to dilative cardiomyopathy, receiving the heart of a 32-year-old donor. Coronary angiography 7 weeks following transplantation revealed a single left coronary artery arising from the left coronary sinus, and as a coronary abnormality the right coronary artery was originating from the proximal left anterior descending branch. Angiographically the single coronary artery showed no stenoses or irregularities. Intravascular ultrasound examination (30 MHz, 3.5-F catheter) demonstrated relevant atherosclerotic lesions along the stem, the proximal and middle portion of the left anterior descending artery, and especially at the origin of the equivalent of the right coronary artery. Thallium-201 stress testing showed only discrete filling defects at the inferior wall. After orthotopic heart transplantation intravascular ultrasound investigation can, in addition to angiography, become extremely relevant especially in heart recipients with a single left coronary artery because vessel wall alterations of the stem and left anterior descending artery may influence the prognosis of these recipients.

Adult↗

[High frequency current catheter ablation in treatment of supraventricular and atrioventricular tachycardia].

Radiofrequency catheter ablation has been established as a first line therapy for the curative treatment of patients with atrioventricular nodal reentrant tachycardia and atrioventricular tachycardia encompassing accessory pathways as well as for ablation of the "normal" AV-junction. For these indications, the success rates exceed 90%. Acute complications during ablation of accessory pathway and ablation of the "normal" AV-junction occur in approximately 2-5% of patients treated. The incidence of complications during modification of the atrioventricular node to cure AV-nodal reentrant tachycardias clearly depends on the ablation technique used. The anterior approach with ablation of the so-called "fast pathway" carries a significantly higher risk of complete AV-block when compared to the inferior approach (so-called "slow pathway ablation") (approximately 4-8% vs. 2%). Arrhythmia recurrence after successful ablation of the "normal" AV-junction occurs only rarely, while the recurrence rate after modification of the AV-node or ablation of accessory pathway is approximately 10% during long-term follow-up. Recently, it has been shown that other, rare types of supraventricular tachycardia (sinus-atrial reentrant tachycardia, ectopic atrial tachycardia, human type I atrial flutter) can also be successfully ablated using radiofrequency current. In addition, first clinical results indicate that modification of anterograde AV-nodal conduction properties in patients with atrial fibrillation and fast ventricular rate by radiofrequency application to postero- and midseptal sites might be a useful therapeutic tool to slow ventricular rate. Because of the high success-rate and the relative low incidence of severe procedure related complications, the indications of radiofrequency ablation procedures for the treatment of supraventricular tachycardias will be extended in the future. In addition, it might be reasonable to expect that during the next years, all types of supraventricular tachycardia, except atrial fibrillation, can be targeted and cured by radiofrequency ablation in the majority of cases.

Atrioventricular Node↗

[Electrophysiologic findings and high frequency catheter ablation in atriofascicular and nodoventricular pathways ("Mahaim bundles")].

So-called "Mahaim-pathways" represent a distinct subset of accessory pathways and the preexcitation syndromes with unique electrophysiologic properties. During sinus rhythm, preexcitation is minimal or absent whereas incremental atrial stimulation reveals preexcitation with a left bundle branch block like morphology. "Mahaim-fibers" exhibit long conduction times, decremental conduction properties by atrial extrastimuli or incremental atrial pacing, and conduction only in the anterograde direction. The typical atrioventricular reentrant tachycardia incorporating a "Mahaim-pathway" is a preexcited antidromic tachycardia with anterograde conduction over the accessory pathway and retrograde conduction over the AV node. "Mahaim-fibers" may be associated with dual AV node physiology or common atrioventricular accessory pathways. The original concept of "Mahaim-fibers" consisted of accessory pathways originating in the AV node and inserting into the distal right bundle branch ("nodofascicular" pathways) or the right ventricle ("nodoventricular" pathways). This understanding has been challenged by surgical interventions identifying the atrial insertion of "Mahaim-pathways" at the parietal tricuspid annulus. Later, electrophysiologic and surgical studies have confirmed the antero-to posterolateral atrial origin of these accessory pathways remote from the atrioventricular node. Therefore, the concept of nodoventricular pathways has been replaced by the concept of atriofascicular pathways. Recently, endocardial catheter mapping and radiofrequency catheter ablation have substantially contributed to the characterization of this unusual form of the preexcitation syndrome. Distinct, high-frequency activation potentials of atriofascicular accessory pathways can be recorded at the atrial insertion at the antero- to posterolateral tricuspid annulus and along the entire ventricular course up to the ventricular insertion in the right ventricular apical region near or at the distal right bundle branch. The long conduction times and the decremental conduction properties result from a delay in the interval from the local atrial activation at the atrial insertion to the activation potential of the accessory pathway whereas the conduction time between the activation potential of the accessory pathway and the local activation at the ventricular insertion is relatively constant. Overall, the current knowledge about atriofascicular pathways is indicative of a proximal AV-node-like component and a distal bundle-branch-like component and, therefore, suggestive of an accessory AV conduction system. Radiofrequency current application for ablation of atriofascicular pathways can be accomplished at their atrial insertion and along their entire ventricular course. Highfrequency activation potentials of the atriofascicular pathways identify target sites for ablation. Transient mechanical conduction block by catheter manipulation at the subannular level of the atrial insertion has also been introduced as a marker for successful ablation of these unusual accessory pathways.

Adult↗

[High frequency current catheter ablation in ventricular tachycardia].

Since its introduction into clinical practice in 1982, catheter ablation has evolved as a first-line mode of non-pharmacological therapy in patients with atrioventricular nodal reentrant tachycardia and in patients with atrioventricular tachycardia involving an accessory pathway. The initial experience was based on the use of direct current for ablative purposes. However, since severe complications have been observed using this energy source, radiofrequency (RF) current catheter ablation is now the most frequently used technique. Efficacy rates are high (> 80%) in patients with idiopathic ventricular tachycardia and bundle-branch reentrant tachycardia. In addition, the technique also has a relatively high acute success-rate in patients with incessant ventricular tachycardia. However, RF current catheter ablation is less effective in patients with drug-resistant, chronic, sustained ventricular tachycardia after myocardial infarction or in the presence of dilated cardiomyopathy. Further improvements which include new criteria for the localization of the origin of ventricular tachycardia as well as technical improvements are particularly needed in this subgroup of patients. Thus, RF current catheter ablation in patients with ventricular tachycardia can be considered a promising new mode of non-pharmacological therapy. The efficacy rate of the procedure is highly dependent on the presence and type of organic heart disease as well as the mechanisms underlying ventricular tachycardia. Due to the limited experience, especially with respect to the long-term results, RF current catheter ablation is still an experimental mode of antiarrhythmic treatment.

Cardiomyopathy, Dilated↗

[Initial experiences with dobutamine stress echocardiography in heart transplant patients].

UNLABELLED: Cardiac allograft vasculopathy (CAV) has become one of the primary obstacles to long-term survival of patients after heart transplantation. The low sensitivity of currently available noninvasive tests still remains a problem in the early diagnosis of the disease. To assess the feasibility, safety, and usefulness of dobutamine stress echocardiography as a noninvasive predictor of cardiac allograft vasculopathy, we examined 20 patients (3 female) 3-35 months after orthotopic heart transplantation. All patients underwent coronary angiography within 2 weeks of dobutamine stress echocardiography. RESULTS: 89% of the segments examined could be evaluated for wall motion abnormalities. Under increasing doses of dobutamine (5 to max. 30 micrograms/kg/min), heart rate increased from 88 +/- 13 bpm to 141 +/- 16 bpm. and systolic blood pressure from 139 +2- 14 mm Hg to 154 +/- 28 mm Hg. Two of 4 patients with angiographically detected CAV developed new wall motion abnormalities under dobutamine; their wall motion score increased from 1.23 +/- 0.22 to 1.31 +/- 0.24. In the other patients without CAV, the wall motion score remained almost unchanged (1.01 +/- 0.3 to 1.02 +/- 0.4). Dobutamine was well tolerated, and there were no serious complications. Thus, dobutamine stress echocardiography seems to be feasible and safe in patients after heart transplantation. Our results suggest that it might be useful for the detection of cardiac allograft vasculopathy. The final determination of its clinical usefulness in the diagnosis of cardiac allograft vasculopathy needs further extensive investigations.

Adult↗

[In vitro validation of intravascular ultrasound, computerized and magnetic resonance tomography in diagnosis of atherosclerotic vascular segments in comparison with direct magnification radiography].

The depiction of atherosclerotic vessel abnormalities is a prerequisite for percutaneous interventional therapy and long-term observations of peripheral artery disease. The aim of this in-vitro study was to determine the potentials and limitations of 12.5 and 20 MHz intravascular ultrasound, computed tomography and magnetic resonance (MR) imaging in comparison to direct magnification radiography for the localization and quantification of peripheral vessel wall calcifications. Forty-three postmortem, human iliac segments were examined by intravascular ultrasound (12.5 and 20 MHz), computed tomography and magnetic resonance tomography (gradient echo-and spin echo-technique). For comparative analysis, each segment was divided into eight sectors of 45 degrees each; using all five methods, the presence of calcified wall areas was examined in each sector, and luminal area (42 segments) and plaque area (32 isolated plaques) were quantitatively estimated. In the sonograms, the circumferential extension of the boundary between intima and media was measured. 122 of 344 sectors showed regional vessel wall calcifications. Sensitivity of 20 MHz intravascular ultrasound was 73% versus 59% with the 12.5 probe, specificity was 97% with 20 MHz, 96% with 12.5 MHz. Sensitivity of both 12.5 and 20 MHz intravascular ultrasound was higher with increased thickness of the calcified structures. 20 MHz ultrasound identified the intima-media boundary averaging 146.8 degrees of the vessel circumference; the corresponding value of 131.8 degree with 12.5 MHz did not differ significantly. Computed tomography detected calcifications with a sensitivity of 88%, specificity was 88%. With MR imaging, sensitivity of the gradient echo-technique was 94% versus a sensitivity of 86% with spin echo-technique. Quantification of luminal and plaque areas showed that luminal area was precisely estimated only by 20 MHz ultrasound (no significant difference to direct magnification radiography), whereas all other techniques showed significant overestimation. Plaque areas were markedly overestimated by computed tomography and MR imaging, too. In an in vitro set-up, intravascular ultrasound, MR tomography and computed tomography do not allow an authentic depiction of peripheral vessel wall architecture. Limited resolution, subintimal shadowing and and distortion are the main limitations of these new techniques so that details of regional vessel wall calcifications cannot be presented thoroughly. Relevant over-estimation of luminal and plaque areas must be considered.

Arteriosclerosis↗

Growth status-dependent changes of bFGF compartmentalization and heparan sulfate structure in arterial smooth muscle cells.

Cultured bovine arterial smooth muscle cells express 6 to 7 ng basic fibroblast growth factor (bFGF)/mg cell protein and distribute it to two compartments. About 80% of total bFGF remain intracellularly, 20% are present in the pericellular (trypsin-releasable) compartment. No bFGF can be detected in the culture medium. All bFGF fractions have full biological activity. They are quantified by a highly specific immunoassay system and identified after sodium dodecyl sulfate polyacrylamide electrophoresis as a 18 kDa double band by immunoblotting. During exponential growth the intracellular concentration of bFGF decreases from about 130 pg to 20 to 40 pg/10(5) cells. Simultaneously the pericellular bFGF increases to 60-70% of total bFGF, but declines continuously with increasing cell density, whereas the intracellular bFGF reincreases under these conditions. The pericellular bFGF is known to form complexes with (membrane integrated) proteoheparan sulfate which undergoes structural changes during transition from subconfluent to confluent growth status. After metabolic labeling of the cells with [35S]sulfate and [3H]glucosamine, the 35S/3H ratio of heparan sulfate oligosaccharides increases from 1.58 during proliferation to 2.47 in growth-inhibited cells. The results indicate that the bFGF-induced proliferation of arterial smooth muscle cells depends on the pericellular localization of bFGF and on a specific molecular organization of the cell surface heparan sulfate. Depending on its specific structural characteristics heparan sulfate may promote or inhibit bFGF receptor binding and signal transduction.

Animals↗

[The idiopathic QT syndrome as the cause of epileptic and nonepileptic seizures].

The long QT syndrome (LQTS) is characterized by a pathological lengthening of the corrected QT interval on the surface ECG and the occurrence of syncopal attacks, sometimes presenting as a seizure disorder. They are caused by ventricular tachycardia of the torsade de pointes type, an arrhythmia that is also responsible for the high incidence of sudden death among these patients. Besides the acquired forms of LQTS which are transient (e.g. therapy with QT-prolonging drugs), congenital variants (Romano-Ward syndrome, Jervell/Lange-Nielsen syndrome, sporadic form) can occur as well. The latter mostly become manifest during childhood or adolescence. Because the syndrome is rare, it is often not included in the primary differential diagnosis of syncope. Thus, misinterpretation as epilepsy may occur. Especially if siblings are affected, a genetic epilepsy may be diagnosed. However, the correct diagnosis can be made by standard ECG methods. Early recognition of the syndrome is very importance because of prognostic and therapeutic consequences. In this article, two cases of idiopathic LQTS are presented. Problems regarding differential diagnosis and therapy are discussed.

Adolescent↗

Response to sotalol predicts the response to amiodarone during serial drug testing in patients with sustained ventricular tachycardia and coronary artery disease.

UNLABELLED: It was analyzed whether the response to sotalol can predict the response to amiodarone as evaluated by programmed ventricular stimulation in 30 patients with coronary artery disease and documented recurrent sustained ventricular tachycardia (VT). Programmed ventricular stimulation was performed using 1 or 2 extrastimuli during sinus rhythm and 4 drive cycle lengths at 2 right ventricular sites. If no ventricular tachyarrhythmia was induced, a third extrastimulus was introduced during a paced cycle length of 500 ms. During the control study, VT (mean cycle length 305 +/- 63 ms) was induced in all patients, and the right ventricular effective refractory period (during S1-S1 = 500 ms) was 223 +/- 12 ms. After sotalol, sustained and nonsustained VT were inducible in 22 (73%) and 7 (23%) patients, respectively. One patient did not undergo stimulation on sotalol, because of side effects. After amiodarone, sustained and nonsustained VT were inducible in 23 (77%) and 7 (23%) patients, respectively. The mean cycle length of the induced VT was prolonged after both drugs by 17% (p < 0.001). The effective refractory period was prolonged by 15% (p < 0.001) after sotalol and by 13% (p < 0.001 compared with baseline study; p = NS between both drugs) after amiodarone. Thus, concordant results (effective or ineffective drug) between sotalol and amiodarone were found in 26 patients (87%). IN CONCLUSION: (1) The effects of sotalol and amiodarone on the cycle length of induced VT and on right ventricular effective refractory period were similar; and (2) inability to suppress VT by amiodarone can be predicted from the response to sotalol.(ABSTRACT TRUNCATED AT 250 WORDS)

Amiodarone↗

Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction.

Patients who suffer from post-infarction depression are a high risk group with an increased mortality risk. The reasons for this are not known although it may be because such patients cannot cope with the chronic condition of cardiac disease. We designed a profile of clinical and behavioural outcome measurements representing recovery after myocardial infarction. 552 male survivors of acute myocardial infarction (29-65 years; mean = 53) were grouped at study entry according to their depression status. 377 patients were reassessed after 6 months and were divided into the following subgroups: 50 (13.3%) patients had severe depression; 85 (22.5%) moderate depression and 242 (64.2%) low degrees of depression in the initial study. There were no substantial differences in baseline characteristics between the index group and the drop-out group. The unadjusted relative risk for follow-up angina pectoris among patients with depression (severe versus low) was 3.12 (95% CI 1.58 to 6.16) and was 5.55 (CI 2.87 to 10.71) for emotional instability. The relative risk for maintenance of smoking habits was 2.63 (CI 1.23 to 5.60) and was for work resumption 0.39 (CI 0.18 to 0.88). There was no association between depression and the occurrence of late potentials. After adjustment for univariate variables (age, social class, recurrent infarction, helplessness) only small and nonsignificant changes in the relative risks were found. However the inverse association of depression and work resumption was lost after adjustment. The investigation revealed that persistent postinfarction depression is an independent and important source of subsequent morbidity and long-acting reduced quality of life. Depression has adverse effects on illness behaviour and pain perception.

Adult↗

The role of implantable cardioverter defibrillators in dilated cardiomyopathy.

Depending on the severity of the disease, patients with dilative cardiomyopathy (DCM) have a poor prognosis. No definite data are available to show that complex ventricular ectopy, the presence of ventricular late potentials, or programmed electrical stimulation in patients without symptoms with DCM identify patients at risk of sudden cardiac death. Although poor left ventricular function seems to be the most potent predictor of total cardiac death, the prediction of sudden death in patients without symptoms with DCM is poor. Studies with either class I antiarrhythmic drugs or amiodarone have not yet demonstrated a reduction in total mortality rates or sudden death. The usefulness of an implantable cardioverter defibrillator (ICD) in patients without symptoms with DCM is currently under investigation. The usefulness of serial electropharmacologic testing for patients with documented sustained ventricular tachycardia or ventricular fibrillation and DCM is still controversial. Because most patients with DCM and VT or out-of-hospital cardiac arrest have either no inducible ventricular tachyarrhythmia at baseline or the reproducibility of ventricular tachycardia/ventricular fibrillation induction is poor, implantation of an ICD should be considered in most of these patients. The indication for implantation of an ICD should be made on clinical judgment of the patient's functional status and other prognosis-limiting factors, such as rapid progression of heart failure, end-stage heart failure, and age.

Anti-Arrhythmia Agents↗